Cyanotech Corporation (CYAN) Hisse Analizi
Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
CYAN, $ (piyasa değeri 0) fiyatla Consumer Defensive işi olan Cyanotech Corporation'i temsil ediyor. Büyüme potansiyeli, finansal sağlık ve momentum konusunda 40/100 (ihtiyatlı) olarak derecelendirilmiştir.
Son analiz: 16 Mar 2026Cyanotech Corporation (CYAN) Tüketici İşletmesi Genel Bakışı
Cyanotech Corporation, founded in 1983, specializes in microalgae-derived products like BioAstin and Spirulina, catering to the health and wellness market. With a focus on dietary supplements, the company distributes through diverse channels, including online, retail, and bulk sales, positioning itself within the competitive packaged foods sector.
Yatırım Tezi
Cyanotech Corporation presents a unique investment proposition within the consumer defensive sector, specifically in the niche market of microalgae-derived health supplements. The company's focus on BioAstin and Spirulina products caters to the growing demand for natural antioxidants and dietary supplements. However, with a negative P/E ratio of -1.35 and a negative profit margin of -7.1%, the company's current profitability is a concern. The gross margin of 32.1% indicates potential for improvement in operational efficiency. Key growth catalysts include expanding distribution channels and increasing consumer awareness of the health benefits of astaxanthin and spirulina. The company's low beta of -0.21 suggests relatively low volatility compared to the market, but investors should carefully consider the risks associated with OTC-traded companies.
FMP finansallarına ve nicel analizine dayanmaktadır
Temel Önemli Noktalar
- Gross Margin of 32.1% indicates potential for profitability improvements through operational efficiencies.
- Negative Profit Margin of -7.1% signals challenges in achieving sustainable profitability.
- Market Cap of $0.00B reflects the company's small size and potential for growth or volatility.
- P/E Ratio of -1.35 indicates the company is currently not profitable, requiring further investigation into its earnings potential.
- Beta of -0.21 suggests the stock is less volatile than the market, potentially offering stability in turbulent times.
Rakipler & Benzerleri
Güçlü Yönler
- Established brand recognition for BioAstin and Spirulina.
- Proprietary cultivation and extraction processes.
- Direct-to-consumer sales channel.
- Unique Hawaiian origin provides a marketing advantage.
Zayıflıklar
- Negative profit margin.
- Limited financial resources compared to larger competitors.
- Reliance on a small number of key products.
- Vulnerability to fluctuations in raw material costs.
Katalizörler
- Ongoing: Expansion of online sales channels to reach a broader customer base.
- Ongoing: Strategic partnerships with retailers and distributors to increase market reach.
- Ongoing: Product innovation and development of new formulations.
- Ongoing: International market expansion to tap into new sources of revenue.
- Ongoing: Increased consumer awareness and education campaigns to drive demand.
Riskler
- Potential: Increased competition from larger nutraceutical companies.
- Potential: Changes in regulatory requirements for dietary supplements.
- Potential: Fluctuations in raw material prices.
- Potential: Negative publicity regarding the safety or efficacy of astaxanthin or spirulina.
- Ongoing: Negative profit margin and limited financial resources.
Büyüme Fırsatları
- Expansion of Online Sales Channels: Cyanotech can capitalize on the growing e-commerce trend by expanding its online sales channels. The global e-commerce market is projected to reach trillions of dollars by 2026. By investing in its online presence, improving its website user experience, and leveraging digital marketing strategies, Cyanotech can reach a broader customer base and increase sales. This includes direct-to-consumer sales and partnerships with online retailers. Timeline: Ongoing.
- Strategic Partnerships and Distribution Agreements: Forming strategic partnerships with major retailers and distributors can significantly expand Cyanotech's market reach. Collaborating with established players in the health and wellness industry can provide access to new markets and customer segments. This includes partnerships with grocery chains, pharmacies, and specialty health stores. Timeline: Ongoing.
- Product Innovation and New Product Development: Investing in research and development to create new and innovative products can drive growth. This includes exploring new applications for astaxanthin and spirulina, as well as developing new formulations and delivery methods. The market for innovative dietary supplements is constantly evolving, and Cyanotech can stay ahead of the curve by introducing novel products that meet consumer needs. Timeline: Ongoing.
- International Market Expansion: Expanding into international markets represents a significant growth opportunity for Cyanotech. The global dietary supplements market is growing rapidly, particularly in emerging economies. By targeting specific regions with tailored marketing strategies and distribution networks, Cyanotech can tap into new sources of revenue and diversify its customer base. Timeline: Ongoing.
- Increased Consumer Awareness and Education: Investing in consumer education and awareness campaigns can drive demand for Cyanotech's products. Many consumers are not fully aware of the health benefits of astaxanthin and spirulina. By educating consumers about the science behind these ingredients and their potential health benefits, Cyanotech can increase demand and build brand loyalty. This includes content marketing, social media engagement, and partnerships with health influencers. Timeline: Ongoing.
Fırsatlar
- Expansion into new international markets.
- Development of new products and formulations.
- Increased consumer awareness of the health benefits of astaxanthin and spirulina.
- Strategic partnerships with major retailers and distributors.
Tehditler
- Increased competition from larger nutraceutical companies.
- Changes in regulatory requirements for dietary supplements.
- Fluctuations in raw material prices.
- Negative publicity regarding the safety or efficacy of astaxanthin or spirulina.
Rekabet Avantajları
- Proprietary cultivation and extraction processes.
- Established brand recognition for BioAstin and Spirulina.
- Location in Hawaii provides a unique selling proposition (USP).
- Long-standing relationships with distributors and retailers.
CYAN Hakkında
Cyanotech Corporation, established in 1983 and headquartered in Kailua-Kona, Hawaii, focuses on the cultivation, production, and sale of natural products derived from microalgae. The company's flagship products include BioAstin Hawaiian Astaxanthin, a dietary antioxidant known for enhancing skin health and supporting eye, joint, and immune function. This product is marketed as a human dietary supplement and dietary ingredient. Another key product is Hawaiian Spirulina Pacifica, a nutrient-rich dietary supplement, promoted for its energy-boosting, immune-strengthening, and cardiovascular benefits, as well as its antioxidant carotenoid content. Cyanotech distributes its products through a variety of channels, including distributors, retailers, and online platforms, directly targeting consumers. Additionally, the company engages in bulk sales to manufacturers, formulators, and distributors within the health foods, nutraceuticals, and dietary supplement industries. The company also provides contract extraction services. Cyanotech's commitment to producing high-quality, microalgae-based products has allowed it to establish a presence in the competitive health and wellness market.
Ne Yaparlar
- Cultivates and produces microalgae.
- Extracts and processes astaxanthin from microalgae.
- Manufactures and packages dietary supplements.
- Sells BioAstin Hawaiian Astaxanthin for skin, eye, joint, and immune health.
- Sells Hawaiian Spirulina Pacifica for energy, immune support, and cardiovascular benefits.
- Provides contract extraction services.
İş Modeli
- Cultivation and production of microalgae-derived products.
- Direct-to-consumer sales through online channels.
- Sales through distributors and retailers.
- Bulk sales to manufacturers and formulators.
Sektör Bağlamı
Cyanotech Corporation operates within the consumer defensive sector, specifically in the packaged foods industry, focusing on dietary supplements. The global dietary supplements market is experiencing steady growth, driven by increasing health awareness and an aging population. Key trends include the rising demand for natural and organic products, as well as the growing popularity of online retail channels. Cyanotech faces competition from other players in the nutraceuticals market. Competitors include companies that offer similar algae-based products and broader dietary supplement brands. The company's success depends on its ability to differentiate its products through quality, branding, and effective marketing.
Kilit Müşteriler
- Health-conscious consumers seeking natural supplements.
- Individuals looking for antioxidant and immune support.
- Manufacturers and formulators in the health foods and nutraceuticals industries.
- Retailers and distributors in the dietary supplement market.
Finansallar
Grafik & Bilgi
Cyanotech Corporation (CYAN) hisse senedi fiyatı: Price data unavailable
Son Haberler
-
Stocks That Hit 52-Week Highs On Thursday
· 7 Oca 2021
-
New 52-Week Lows For Monday Morning
· 5 Ağu 2019
Analist Konsensüsü
Fikir Birliği Derecelendirmesi
CYAN için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.
Fiyat Hedefleri
CYAN için Wall Street fiyat hedefi analizi.
MoonshotScore
Bu puan ne anlama geliyor?
MoonshotScore, CYAN'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.
Rakipler & Benzerleri
Yönetim: Matthew Keith Custer
CEO
Matthew Keith Custer serves as the CEO of Cyanotech Corporation, overseeing the company's operations and strategic direction. Information regarding his detailed career history, education, and previous roles is not available in the provided source data. As CEO, he is responsible for managing the company's 77 employees and driving its growth in the competitive nutraceuticals market. His leadership is crucial for navigating the challenges and opportunities facing Cyanotech in the evolving health and wellness industry.
Sicil: Due to the limitations of the provided source data, specific achievements, strategic decisions, and company milestones under Matthew Keith Custer's leadership cannot be detailed. His tenure and impact on Cyanotech's performance require further investigation beyond the available information. Assessing his track record would involve analyzing the company's financial performance, product innovation, and market share growth during his time as CEO.
CYAN OTC Piyasa Bilgileri
The OTC Other tier represents the lowest tier of the OTC market, indicating that Cyanotech Corporation may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited financial disclosure, which increases investment risk. Trading on the OTC Other market typically involves less stringent listing requirements compared to major exchanges like the NYSE or NASDAQ, resulting in potentially less transparency and regulatory oversight. Investors should exercise caution and conduct thorough due diligence before investing in companies on this tier.
- OTC Katmanı: OTC Other
- Açıklama Durumu: Unknown
- Limited financial disclosure due to the OTC Other tier.
- Lower trading volume and liquidity compared to major exchanges.
- Potential for wider bid-ask spreads.
- Increased price volatility.
- Less stringent regulatory oversight.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's revenue and earnings growth potential.
- Analyze the company's cash flow and debt levels.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- The company has been in operation since 1983.
- Cyanotech has established brand recognition for BioAstin and Spirulina.
- The company has a direct-to-consumer sales channel.
- Cyanotech has a physical presence with its headquarters in Kailua-Kona, Hawaii.
Yatırımcılar Cyanotech Corporation (CYAN) Hakkında Ne Soruyor
CYAN için değerlendirilmesi gereken temel faktörler nelerdir?
Cyanotech Corporation (CYAN) şu anda yapay zeka skoru 40/100, düşük puanı gösteriyor. Temel güçlü yan: Established brand recognition for BioAstin and Spirulina.. İzlenmesi gereken birincil risk: Potential: Increased competition from larger nutraceutical companies.. Bu bir finansal tavsiye değildir.
CYAN MoonshotScore'u nedir?
CYAN şu anda MoonshotScore'da 40/100 (Derece D) alıyor, bu da düşük derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.
CYAN verileri ne sıklıkla güncellenir?
CYAN fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.
Analistler CYAN hakkında ne diyor?
CYAN için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.
CYAN'a yatırım yapmanın riskleri nelerdir?
CYAN için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Potential: Increased competition from larger nutraceutical companies.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.
CYAN'ın P/E oranı nedir?
CYAN için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için CYAN'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.
CYAN aşırı değerli mi, yoksa düşük değerli mi?
Cyanotech Corporation (CYAN)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.
CYAN'ın temettü verimi nedir?
Cyanotech Corporation (CYAN) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.
Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.
Resmi Kaynaklar
Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.
- Limited information available on CEO's background and track record.
- OTC analysis based on general characteristics of the OTC Other tier.